CynthiaReese CaulfieldOsborneMD

Oncology • Dallas, TX

Physician

Join to view full profile

Dr. Osborne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Osborne's full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1000

Fax+1 972-370-1850

Education & Training

University of Texas Medical Branch HospitalsFellowship, Geriatric Medicine (Internal Medicine), 2001 - 2002
University of Texas Medical Branch HospitalsFellowship, Medical Oncology, 1999 - 2001
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 1996 - 1999
University of Texas Medical Branch School of MedicineClass of 1996

Certifications & Licensure

TX State Medical License 1999 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Ixabepilone + Carboplatin Metastatic Breast Cancer Start of enrollment: 2010 Jan 01
Completed
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3

Publications & Presentations

PubMed

2 citations
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...
Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10
29 citations
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A Hurvitz, Shanu Modi
Cancer Discovery. 2022-12-02
57 citations
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Aditya Bardia, Virginia G. Kaklamani, Sharon Wilks, Amy Weise, Donald A. Richards
Journal of Clinical Oncology. 2021-01-29

Press Mentions

Day Care Will Never Be Germ-Free. But We Can Make It Less GrossDecember 16th, 2022
Orally Bioavailable SERD Shows Promise in Certain Breast Cancer PatientsJanuary 31st, 2021
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024